Celator Pharmaceuticals Company Profile (NASDAQ:CPXX)

About Celator Pharmaceuticals

Celator Pharmaceuticals logoCelator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company's technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company's product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CPXX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $28.68
  • 200 Day Moving Average: $12.63
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -91.64
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 7.09
Additional Links:
Companies Related to Celator Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Celator Pharmaceuticals (NASDAQ:CPXX) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $21.20 (29.89% downside)

Analysts' Ratings History for Celator Pharmaceuticals (NASDAQ:CPXX)
DateFirmActionRatingPrice TargetDetails
6/1/2016Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details
6/1/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details
5/31/2016Needham & Company LLCDowngradeBuy -> HoldView Rating Details
5/31/2016Roth CapitalDowngradeBuy -> Neutral$30.25 -> $26.00View Rating Details
3/15/2016HC WainwrightBoost Price TargetBuy$20.00View Rating Details
10/30/2015FBR & CoReiterated RatingOutperformView Rating Details
8/12/2015MLV & Co.Reiterated RatingBuy$6.00View Rating Details
(Data available from 2/23/2015 forward)


Earnings History for Celator Pharmaceuticals (NASDAQ:CPXX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q116($0.15)($0.16)ViewListenView Earnings Details
3/21/2016Q4($0.12)($0.13)ViewN/AView Earnings Details
11/12/2015Q315($0.16)($0.15)ViewListenView Earnings Details
8/11/2015Q215($0.14)($0.15)ViewListenView Earnings Details
5/7/2015($0.14)($0.14)ViewN/AView Earnings Details
3/17/2015($0.16)($0.07)ViewN/AView Earnings Details
11/13/2014($0.21)($0.21)ViewN/AView Earnings Details
8/11/2014($0.20)($0.18)ViewN/AView Earnings Details
5/13/2014($0.24)($0.16)ViewN/AView Earnings Details
3/24/2014Q4 13($0.15)($0.13)ViewN/AView Earnings Details
11/12/2013($0.20)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Celator Pharmaceuticals (NASDAQ:CPXX)
Current Year EPS Consensus Estimate: $-0.60 EPS
Next Year EPS Consensus Estimate: $-0.33 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.15)($0.15)($0.15)
Q2 20162($0.15)($0.14)($0.15)
Q3 20162($0.16)($0.14)($0.15)
Q4 20162($0.18)($0.13)($0.16)
(Data provided by Zacks Investment Research)


Dividend History for Celator Pharmaceuticals (NASDAQ:CPXX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celator Pharmaceuticals (NASDAQ:CPXX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/3/2015Scott D MorensteinDirectorBuy5,000$1.87$9,350.00View SEC Filing  
10/6/2015Scott Thomas JacksonCEOBuy14,450$1.74$25,143.00View SEC Filing  
10/5/2015Fred M PowellCFOBuy13,700$1.78$24,386.00View SEC Filing  
10/1/2015Life Sciences Gp Ll Valence IIinsiderBuy12,200$1.64$20,008.00View SEC Filing  
11/18/2014Fred M PowellCFOBuy6,000$2.20$13,200.00View SEC Filing  
11/18/2014Michael R DoughertyDirectorBuy20,000$2.15$43,000.00View SEC Filing  
11/18/2014Scott Thomas JacksonCEOBuy10,000$2.20$22,000.00View SEC Filing  
5/15/2014Fred M PowellCFOBuy2,500$2.50$6,250.00View SEC Filing  
12/17/2013Fred M PowellCFOBuy2,500$3.50$8,750.00View SEC Filing  
12/17/2013Scott Thomas JacksonCEOBuy3,000$3.50$10,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Celator Pharmaceuticals (NASDAQ:CPXX)
gurufocus.com logoCellectar Biosciences' PDC Delivery Platform May Advance Treatment of Multiple Myeloma - GuruFocus.com (NASDAQ:CPXX)
www.gurufocus.com - February 13 at 5:11 PM
gurufocus.com logoActinium Pharmaceuticals Is Better Than Celator - GuruFocus.com (NASDAQ:CPXX)
www.gurufocus.com - February 7 at 5:34 PM
finance.yahoo.com logoActinium Pharmaceuticals Is Better Than Celator (NASDAQ:CPXX)
finance.yahoo.com - February 7 at 5:34 PM
News IconAre Analysts Predicting a Near-Term Upswing For Celator Pharmaceuticals Inc. (NASDAQ:CPXX)? - Wall Street Beacon (NASDAQ:CPXX)
wsbeacon.com - February 1 at 3:44 AM
News IconBrokers Release Average Price Target Of 15.25 On Celator Pharmaceuticals Inc. (CPXX) - UK Market News (NASDAQ:CPXX)
www.ukmarketnews.co.uk - January 26 at 5:36 PM
News IconEarnings in Full Force, Analysts Take Aim at Celator Pharmaceuticals Inc. (NASDAQ:CPXX) - Wall Street Beacon (NASDAQ:CPXX)
wsbeacon.com - January 26 at 5:36 PM
News IconReviewing Individual Broker Targets Of Celator Pharmaceuticals Inc. (CPXX) - NewsDen (NASDAQ:CPXX)
newsden.net - January 23 at 4:49 PM
News IconStock Buzzer: What's Propelling Tata Motors Limited (ADR) to Increase So Much? - Fair View Times (NASDAQ:CPXX)
fairviewtimes.com - January 18 at 9:48 PM
News IconToday Tata Motors Limited (ADR) Had High Bearish Options Activity ... - Fair Herald (NASDAQ:CPXX)
fairherald.com - January 17 at 10:23 PM
News IconTata Motors Ltd. (TTM) Upgrade at the Sanford C. Bernstein (NASDAQ:CPXX)
larampadinapoli.com - December 30 at 9:54 PM
News IconCelator Pharmaceuticals, Inc. CPXX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CPXX)
www.bioportfolio.com - November 25 at 9:40 AM
News IconRatings Don't Lie: Tata Motors (NYSE:TTM)'s Is Reaching An Inflection Point; Bernstein Upgrades It - Thorold News (NASDAQ:CPXX)
www.whatsonthorold.com - November 21 at 10:27 PM
tmcnet.com logoHercules' Portfolio Update for Q3 2016 Highlights Continued Execution of Its Portfolio and Earnings Growth Strategy (NASDAQ:CPXX)
www.tmcnet.com - October 5 at 9:34 AM
prnewswire.com logoJazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission ... - PR Newswire (press release) (NASDAQ:CPXX)
www.prnewswire.com - October 3 at 4:14 PM
News IconJazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission ... - PR Newswire UK (press release) (NASDAQ:CPXX)
www.prnewswire.co.uk - October 3 at 9:10 AM
News IconCurrent Price Targets For Celator Pharmaceuticals Inc. (CPXX) - NewsDen (NASDAQ:CPXX)
newsden.net - September 30 at 9:28 AM
insidermonkey.com logoRA Capital’s Top Q2 Performers; Predicts Big Things Ahead for Pharma Stocks (NASDAQ:CPXX)
www.insidermonkey.com - August 17 at 9:55 AM
prnewswire.com logoWith Impressive Data in Tow, Actinium Pharma An Overlooked ... - PR Newswire (press release) (NASDAQ:CPXX)
www.prnewswire.com - August 10 at 10:34 PM
marketexclusive.com logoMoleculin Biotech Inc (NASDAQ:MBRX): Proceed With Caution (NASDAQ:CPXX)
marketexclusive.com - July 27 at 12:29 PM
4-traders.com logoActinium: Another Promising Name in the AML Space (NASDAQ:CPXX)
www.4-traders.com - July 27 at 12:29 PM
News IconInvestor News: Lawsuit against Buyout of Celator Pharmaceuticals Inc (NASDAQ:CPXX) filed - GroundReport (NASDAQ:CPXX)
www.groundreport.com - July 15 at 10:19 AM
News IconInvestor News: Lawsuit against Buyout of Celator Pharmaceuticals Inc (NASDAQ:CPXX) filed (NASDAQ:CPXX)
www.groundreport.com - July 13 at 4:29 PM
marketrealist.com logoA Look at Jazz Pharmaceuticals’ Celator Acquisition Deal (NASDAQ:CPXX)
marketrealist.com - July 13 at 3:51 PM
marketrealist.com logoWhy Did Jazz Fall after Celator Acquisition Announcement? (NASDAQ:CPXX)
marketrealist.com - July 13 at 3:51 PM
biz.yahoo.com logoCELATOR PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisi (NASDAQ:CPXX)
biz.yahoo.com - July 12 at 4:02 PM
streetinsider.com logoJazz Pharmaceuticals (JAZZ) Offers Results from Celator Pharma (CPXX) Tender Offer - StreetInsider.com (NASDAQ:CPXX)
www.streetinsider.com - July 12 at 8:40 AM
publicnow.com logoJazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares of Common Stock of Celator Pharmaceuticals, Inc. (NASDAQ:CPXX)
www.publicnow.com - July 12 at 2:03 AM
finance.yahoo.com logoSteven Cohen Hits Another Home Run in Oncology (NASDAQ:CPXX)
finance.yahoo.com - July 7 at 1:33 PM
publicnow.com logoHercules Provides Portfolio Update for Q2 2016 and Highlights Con ... (NASDAQ:CPXX)
www.publicnow.com - July 5 at 12:01 PM


What is Celator Pharmaceuticals' stock symbol?

Celator Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPXX."

Where is Celator Pharmaceuticals' stock going? Where will Celator Pharmaceuticals' stock price be in 2017?

5 brokers have issued 1-year target prices for Celator Pharmaceuticals' shares. Their forecasts range from $13.00 to $26.00. On average, they anticipate Celator Pharmaceuticals' stock price to reach $21.20 in the next twelve months.

When will Celator Pharmaceuticals announce their earnings?

Celator Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 9th 2016.

How do I buy Celator Pharmaceuticals stock?

Shares of Celator Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Celator Pharmaceuticals stock cost?

One share of Celator Pharmaceuticals stock can currently be purchased for approximately $30.24.

Celator Pharmaceuticals (NASDAQ:CPXX) Chart for Thursday, February, 23, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)

Earnings History Chart

Earnings by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)

Dividend History Chart

Dividend Payments by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)

Last Updated on 2/23/2017 by MarketBeat.com Staff